US Market for Hemostasis Devices - 2016 (Forecasted to 2022)
|出版商||iData Research Inc.||商品編碼||344800|
|出版日期||內容資訊||英文 48 Pages
|止血設備的美國市場：2016年 (2022年為止的預測) US Market for Hemostasis Devices - 2016 (Forecasted to 2022)|
|出版日期: 2015年10月01日||內容資訊: 英文 48 Pages||
凝血酵素原時間 (PT) 、凝血時間 (TT) 、活化部分凝血活酵素時間 (APTT) 、及D-二聚體等定期性數量許多檢驗，構成止血檢驗整體65％以上。由於人口的高齡化、患者保護、醫療費負擔合理化法 (ACA)，數百萬人包含到健康保險，使定期性的止血檢驗的需求增大。可是，由於有責任的醫療組織 (ACO) 的登場，從付費服務制 (FFS：fee-for-service) 模式轉換為以成果為基礎的醫療費償付模式，使POC檢驗的數量增加，促進核心實驗室站及索引實驗室雙方每一機關的數量、成本下降。
本報告提供美國的止血設備市場相關分析、市場整體結構和近幾年的市場形勢、資本交易趨勢調查、各領域 (血液分析設備、試劑) 的市場結構和市場規模趨勢 (治療數量等) 詳細趨勢估計、考察。
This segment includes only the analyzers and reagents used in core labs of hospitals and in independent commercial labs, without taking into consideration the point-of-care (POC) equipment. The U.S. hemostasis testing is a well-established market, with nearly every hospital and reference lab having an analyzer, and most large hospitals having a backup unit in addition to their primary analyzer. The matured nature of the market and high installed base has led to relatively stable annual unit sales, with replacement of the older machines accounting for a majority of the total sales.
Routine high volume tests such as prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) and D-dimer account for more than 65% of the total hemostasis tests. Tests for monitoring anticoagulant therapies are expected to decrease as new anticoagulant drugs that do not require monitoring are expected to enter the market. Aging population and the inclusion of millions of people into the health insurance bracket due to the Affordable Care Act (ACA) will create increased demand for routine hemostasis tests. However, transitioning to outcome-based reimbursements model from fee-for-service model, due to the emergence of accountable care organizations (ACOs), will increase POC testing volumes, thus driving down the volumes and cost per test at both core lab sites and reference labs.
The competitive analysis outlines Siemens Healthcare Diagnostics as a leader in this market segment, but with Instrumentation Laboratory and other close behind.
This Report includes extensive detail on:
This Report Also Includes:
To Get The Most Out Of This Report:
Combine it with our other US market reports on, Hematology, Immunochemistry, Molecular Diagnostics, Blood Donor Screening, or Point of Care Diagnostic Devices.